Cushing Syndrome Pathogenesis and Clinical Consequences

Etiologic Mechanisms

• Ectopic ACTH secretion occurs when non-pituitary tumors produce ACTH or corticotropin-releasing hormone (CRH), stimulating excessive adrenal cortisol production, with thymic sources accounting for up to 2% of cases, according to the National Comprehensive Cancer Network 1
• Benign adrenal adenomas are unilateral cortisol-secreting tumors that suppress ACTH and are managed with laparoscopic adrenalectomy, as recommended by the National Comprehensive Cancer Network 1, 2
• Adrenal carcinomas are suspected when tumors exceed 5 cm, demonstrate irregular margins, inhomogeneity, or local invasion, according to the National Comprehensive Cancer Network 2

Pathophysiologic Mechanisms

• Mineralocorticoid receptor activation by excess cortisol increases renal sodium absorption, contributing significantly to hypertension development, as reported in Hypertension 3
• Multiple additional pathways promote cardiovascular and metabolic dysfunction, including activation of the renin-angiotensin system, sensitization of vasculature to catecholamines, and impairment of endogenous nitric oxide bioavailability, as reported in Hypertension 3

Clinical Consequences

• Multisystem morbidity develops from chronic glucocorticoid excess, manifesting as weight gain, abdominal striae, hirsutism, dorsal and supraclavicular fat accumulation, fragile skin, mood disorders, menstrual irregularities, and muscle weakness, as reported in Hypertension 3
• Metabolic syndrome mimicry occurs with hypertension and glucose abnormalities being particularly common, exceeding 80% prevalence in cohort studies, as reported in Hypertension 3

Diagnostic Distinction

• Elevated ACTH levels indicate the excessive cortisol is not originating from the adrenal gland itself, pointing toward pituitary tumors or ectopic sources, according to the National Comprehensive Cancer Network 1, 2

Cushing's Syndrome

Understanding Human Cushing's Syndrome

• Cushing's syndrome in humans is a relatively uncommon endocrine disorder caused by chronic excessive glucocorticoid exposure from either endogenous or exogenous sources, according to the American Heart Association, with an estimated incidence due to endogenous overproduction of cortisol, presenting with characteristic symptoms including weight gain, abdominal striae, hirsutism, dorsal and supraclavicular fat accumulation, fragile skin, mood disorders, menstrual irregularities, and muscle weakness 4, 5, 6.
• Hypertension and glucose abnormalities are common, mimicking a severe form of metabolic syndrome, as stated by the American Heart Association 4, 5.

Causes of Human Cushing's Syndrome

• The majority of cases (75-80% in children/adolescents and 49-71% in adults) are caused by pituitary adenomas secreting ACTH, as reported by the Endocrine Society 7.
• Ectopic ACTH-producing tumors, including those in the thymus, account for a small percentage of cases (up to 2% for thymic sources), according to the Endocrine Society 8.

Occupational Considerations

• None of the available medical guidelines or research evidence suggests an occupational link between working with horses and developing human Cushing's syndrome, as stated by the American Heart Association and the Endocrine Society 4, 5, 6, 7, 8.

Cushing's Syndrome Diagnosis and Screening

Clinical Features and Screening Approach

• Mood disorders, depression, and anxiety occur in both Cushing's syndrome and perimenopause, making differentiation challenging based on psychiatric symptoms alone, according to the Endocrine Society 9
• Hypertension and glucose abnormalities exceed 80% prevalence in Cushing's syndrome, mimicking metabolic syndrome that can accompany perimenopause, as reported by the American Heart Association 10
• The American College of Endocrinology recommends screening for Cushing's syndrome in perimenopausal-aged women with menstrual irregularities who also have unexplained central hypogonadism, multiple features of hypercortisolism, or severe hypertension 10
• The Endocrine Society suggests using one or more of the following first-line screening tests: 24-hour urinary free cortisol, late-night salivary cortisol, or 1 mg overnight dexamethasone suppression test, with sensitivities ranging from 89-95% 11

Diagnostic Implications

• The average diagnostic delay in Cushing's syndrome is 3 years from initial symptoms to diagnosis, and this delay is likely prolonged when symptoms are attributed to perimenopause, resulting in increased mortality from cardiovascular events, according to the American Heart Association 10
• Timely diagnosis of Cushing's syndrome is critical for reducing morbidity and mortality, as it causes severe multisystem morbidity, as emphasized by the Endocrine Society 9

Cushing's Disease Clinical Manifestations

Dermatological Features

• The American College of Cardiology and other guideline societies do not recognize excessive sweating as a common or characteristic clinical feature of primary Cushing's disease, instead focusing on other dermatological and metabolic features 12

Systemic Manifestations

• Glucose abnormalities exceed 80% prevalence in Cushing's disease patients, according to the American Heart Association 12
• The Endocrine Society notes that hypertension occurs in 70-90% of patients with Cushing's disease 12

Differentiating Cushing's Syndrome from Metabolic Syndrome

Key Clinical Discriminators

• The American College of Cardiology recommends screening for Cushing's syndrome in patients with metabolic syndrome features who also have rapid weight gain with central distribution, wide (≥1 cm) violaceous striae, proximal muscle weakness, or easy bruising, as these features distinguish pathologic hypercortisolism from simple metabolic syndrome 13, 14
• Wide purple striae (≥1 cm) on abdomen, thighs, or arms are a key feature that distinguishes Cushing's syndrome from metabolic syndrome, according to the American College of Cardiology and Hypertension guidelines 13, 14
• Proximal muscle weakness affecting hip flexors and shoulder girdle is a critical discriminator, causing difficulty rising from a chair or lifting objects overhead, as noted by the American College of Cardiology and Hypertension 13, 14
• Rapid weight gain over months rather than years, particularly with central distribution, is a feature that warrants screening for Cushing's syndrome, as recommended by the American College of Cardiology and Hypertension 13, 14
• Hypertension occurs in 70-90% of Cushing's syndrome patients, but is also common in metabolic syndrome, according to Hypertension guidelines 15
• The American College of Cardiology recommends using one or more first-line tests, including overnight 1-mg dexamethasone suppression test, 24-hour urinary free cortisol, or late-night salivary cortisol, with 89-95% sensitivity, to screen for Cushing's syndrome 13, 14
• Mineralocorticoid receptor antagonists, such as spironolactone or eplerenone, are recommended as first-line agents for hypertension control in Cushing's syndrome, as they can effectively block the excess cortisol activation of mineralocorticoid receptors, according to Hypertension guidelines 15

Hypertension Associated with Exogenous Cushing’s Syndrome

Clinical Presentation

• Severe hypertension (blood pressure ≈ 170/108 mm Hg) observed in patients exhibiting classic Cushingoid features such as moon face, buffalo hump, and easy bruising 16.

Differential Diagnosis

• In patients with systemic lupus erythematosus, immune‑complex nephropathy may be considered, but the presence of Cushingoid signs points to glucocorticoid‑induced hypertension rather than lupus nephritis 16.
• Primary essential hypertension does not account for the characteristic Cushingoid physical findings, supporting glucocorticoid excess as the underlying cause 16.

Epidemiology

• Hypertension is reported in 70–90 % of individuals with Cushing’s syndrome, regardless of whether the source is endogenous or exogenous 16.

Pathophysiology

• The principal mechanism is cortisol‑mediated overload of the 11β‑hydroxysteroid dehydrogenase type 2 enzyme, leading to inappropriate activation of mineralocorticoid receptors and enhanced renal sodium reabsorption 16.

Management Recommendations

• First‑line antihypertensive therapy should prioritize mineralocorticoid‑receptor antagonists (e.g., spironolactone or eplerenone) because they directly counteract cortisol‑driven sodium retention 16.